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Abstract BIA 3-202 is a novel catechol-O-methyltrans-
ferase (COMT) inhibitor being developed for use as a
levodopa-sparing agent in Parkinsons disease. This study
investigated the effect of four single oral doses of BIA
3-202 (50 mg, 100 mg, 200 mg, and 400 mg) compared
with placebo on plasma concentrations of levodopa and
its metabolite 3-O-methyl-levodopa (3-OMD) and on
inhibition of erythrocyte COMT in healthy subjects
receiving 100 mg of levodopa and 25 mg of benserazide
(Madopar 125). This was a single-centre, double-blind,
placebo-controlled, randomised, crossover study with
five single-dose treatment periods. The washout period
between doses was 2 weeks. On each treatment period, a
different dose of BIA 3-202 or placebo was administered
concomitantly with Madopar 125. Tolerability was
assessed by recording adverse events, vital signs, contin-
uous electrocardiogram and clinical laboratory parame-
ters. In the study, 18 subjects (12 male and 6 female)
participated. The drug combination was well tolerated.
All doses of BIA 3-202 significantly increased the area
under the concentration–time curve (AUC) versus
placebo, ranging from 39% (95% confidence intervals,
1.06–1.69) with 50 mg to 80% (95% confidence intervals,
1.42–2.22) with 400 mg. No significant change in mean
maximum plasma concentrations (Cmax) of levodopa was
found. Mean Cmax and AUC of 3-OMD significantly
decreased for all doses tested. BIA 3-202 caused a rapid
and reversible inhibition of S-COMT activity, ranging
from 57% (50 mg) to 84% (400 mg). In conclusion, the
novel COMT inhibitor BIA 3-202 was well tolerated and
significantly increased the bioavailability of levodopa and
reduced the formation of 3-OMD when administered
with standard release levodopa/benserazide.
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Introduction
Parkinsons disease is an age-related neurodegenerative
disorder that affects approximately 1% of people aged
over 60 years and accounts for approximately 75% of
demand of services in movement-disorder clinics [1, 2, 3].
Despite the introduction of new antiparkinsonian drugs
in the last decade, the most effective therapy in Parkin-
sons disease is still levodopa, the immediate precursor
of dopamine [2]. In order to prevent its metabolism by
aromatic L-amino acid decarboxylase (AADC) to
dopamine in the periphery, levodopa is routinely
administered in combination with an AADC inhibitor
(benserazide or carbidopa). However, when adminis-
tered with carbidopa or benserazide, a considerable
amount of levodopa is converted to 3-O-methyl-levo-
dopa (3-OMD) by peripheral catechol-O-methyltrans-
ferase (COMT), and only one-tenth of the administered
dose reaches the brain [4]. The rationale behind the use
of COMT inhibitors in combination with levodopa/
benserazide or levodopa/carbidopa is to (i) increase the
levodopa availability to the brain, while inhibiting the
peripheral O-methylation of levodopa, (ii) improve
the transport of levodopa across the blood–brain barrier,
since 3-OMD competes with levodopa for transport into
the brain [5] and (iii) reduce fluctuations in plasma and
brain levels of levodopa, avoiding the exposure of brain
dopamine receptors to alternating high and low con-
centrations of dopamine [2]. In fact, improved stability
of levodopa plasma levels may reduce the risk for the
development of motor complications [6, 7]. The COMT
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inhibitors clinically developed to date are tolcapone and
entacapone. Tolcapone has been withdrawn from many
countries due to hepatotoxicity. In the USA, the clinical
use of tolcapone requires close monitoring of liver
function. No cases of liver dysfunction have been
attributed to entacapone, but its effectiveness as an ad-
junct to levodopa therapy in Parkinsons disease is
generally considered to be lower than that for tolcapone
[8, 9, 10]. Another difference between tolcapone and
entacapone is that the former crosses the blood–brain
barrier and inhibits COMT both in the periphery and
brain, whereas entacapone is a selective peripheral
COMT inhibitor [11]. However, the usefulness of inhi-
bition of brain COMT has not been established for the
treatment of Parkinsons disease [12].
BIA 3-202 (1-[3,4-dihydroxy-5-nitrophenyl]-2-phe-
nyl-1-ethanone) is a novel COMT inhibitor currently
under clinical development. Studies in laboratory ani-
mals have shown that BIA 3-202 is much more potent at
inhibiting COMT in the periphery than in the brain [13,
14]. In liver homogenates from rats administered orally
with BIA 3-202, tolcapone or entacapone, BIA 3-202
was found to be equipotent with tolcapone in inhibiting
liver COMT, this being more sustained and intense than
that with entacapone [14]. At tmax, inhibition of liver
COMT was similar for BIA 3-202 and tolcapone, but
BIA 3-202 was clearly less potent than tolcapone in
inhibiting brain COMT [14]. In several animal models,
concomitant administration of BIA 3-202 with levodopa
plus benserazide increased in a time- and dose-depen-
dent manner the availability of levodopa to the brain,
this being accompanied with increases in plasma levo-
dopa AUC values [15, 16, 17]. In an entry-into-man
study in healthy male subjects, single doses of 10–
800 mg BIA 3-202 were well tolerated [18]. The safety
profile did not differ from that of placebo. Systemic
exposure to BIA 3-202 increased in an approximately
dose-proportional manner. Food did not affect BIA 3-
202 bioavailability. A good safety profile was also shown
in a multiple dose study in healthy volunteers adminis-
tered with four dosing regimens (50 mg b.i.d., 100 mg
b.i.d., 200 b.i.d., and 200 mg t.i.d.) of BIA 3-202 for
8 days (Almeida and Soares-da-Silva, unpublished
observations). Safety parameters did not differ from
placebo. BIA 3-202 reduced soluble COMT (S-COMT)
activity in erythrocytes, in a dose-dependent manner.
The aim of the present study was to investigate the
tolerability and the pharmacokinetic and pharmacody-
namic (inhibition of erythrocyte S-COMT activity)
interactions between standard release 100/25 mg levo-
dopa/benserazide and single oral doses of 50 mg, 100 mg,
200 mg, 400 mg of BIA 3-202 in healthy subjects.
Methods
Study design and ethics compliance
This was a double-blind, randomised, placebo-controlled, cross-
over study with five single-dose treatment periods, with washout
periods of approximately 2 weeks between doses. The study was
conducted at BIALs Human Pharmacology Unit (S. Mamede do
Coronado, Portugal) according to the principles of the Declaration
of Helsinki and the Good Clinical Practice (ICH) guidelines. An
independent ethics committee (Comissa˜o de E´tica Independente da
UFH, Porto, Portugal) reviewed and approved the study protocol
and supervised the study activities. Written informed consent was
obtained for each volunteers prior to enrolment in the study.
Volunteers were admitted to the unit approximately 24 h prior to
receiving the study medication and remained in the unit under
clinical observation for at least 30 h post-dose, in each treatment
period. All subjects attended the five treatment periods and, in each
period, randomly received a different dose of BIA 3-202 or placebo.
Tablets of 50, 100, 200 and 400 mg BIA 3-202, and placebo tablets
identical in appearance were used. Tablets containing BIA 3-202
were manufactured by BIAL (S. Mamede do Coronado, Portugal)
in accordance with Good Manufacturing Practice. Standard-re-
lease 100/25 mg levodopa/benserazide tablets (Madopar 125,
Roche Farmaceˆutica Quı´mica, Amadora, Portugal) were adminis-
tered concomitantly with BIA 3-202.
Subjects
Eighteen healthy male and female volunteers aged 18–45 years and
with a body mass index of 19–28 kg/m2 participated in the study.
The healthy status was assessed on the basis of a medical history,
physical examination, electrocardiogram (ECG), and clinical lab-
oratory safety tests (haematology, coagulation, plasma biochem-
istry, urinalysis, and hepatitis B, hepatitis C and HIV serology).
Tests for drugs of abuse, and a pregnancy test in females, were
performed at screening and each admission. Though it is known
that BIA 3-202 was devoid of teratogenic effects in laboratory
animals (BIALs data on file), females were required to use effective
contraceptive methods throughout the study. No concomitant
medication was allowed during the study, except if required for
treatment of adverse events. During in-house staying, a standard
diet was served and alcohol-, caffeine- and grapefruit-containing
food and beverages were prohibited. Smoking was not allowed.
Assessment procedures
At screening, a complete medical history and physical examination
were performed and updated at each admission. During each
admission, supine and standing blood pressure, heart rate and a
brief neurological examination were obtained at frequent intervals;
continuous lead-II ECG monitoring was performed 0–4 h post-
dose; 12-lead ECG recordings were obtained at pre-dose, and 1 h
and 30 h post-dose. Clinical laboratory tests (haematology, plasma
biochemistry, and urinalysis) were performed at each admission
and 24 h post-each dose. A follow-up visit occurred approximately
2 weeks after last dosing; then, the medical history and physical
examination were updated, and 12-lead ECG and clinical labora-
tory safety tests were performed.
All clinical adverse events were monitored throughout the entire
study period. Their severity (intensity) was categorised according to
a three-point scale (mild, moderate, and severe) and the causality
(potential relationship to drug) was assessed by the investigator
before breaking the blinding.
Blood sampling and assay of plasma levodopa and 3-OMD
In each treatment period, blood samples (10 ml) were taken pre-
dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18 and 24 h post-dose. Blood
samples were drawn either by direct venipuncture or via an intra-
venous catheter. Blood samples were taken into vacutainers con-
taining potassium ethylene diamine tetraacetic acid (EDTA) and
centrifuged immediately (1500·g, 10 min, 4C). The resulting
plasma was separated into six 0.8-ml aliquots and stored at )70C
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until required for analysis. Plasma concentrations of levodopa and
3-OMD were assayed by the Laboratory of Pharmacological Re-
search, BIAL (S Mamede do Coronado, Portugal), using a vali-
dated method. Briefly, samples were allowed to thaw at room
temperature and an aliquot of plasma (500 ll) with 50 ll of an
antioxidant [sodium metabisulfite 10% (w/v)] were used for the
assay of levodopa. After adding 10 ll of internal standard (di-
hydroxybenzylamine, DHBA; 10 lg/ml), levodopa was extracted
from the plasma using an automated solid-phase extraction tech-
nique with alumina A cartridges (Set-Pak 100 mg, 1 cc Waters).
Plasma concentrations of levodopa were determined using reverse-
phase high-performance liquid chromatography (RP-HPLC) with
electrochemical detection (Gilson), over a range of 50 ng/ml to
500 ng/ml. For the determination of 3-OMD, samples were allowed
to thaw at room temperature and plasma aliquots (600 ll) were
spiked with 12 ll internal standard (metanephrine 50 lg/ml). The
deproteinization was performed by adding 88 ll 0.01 M HCl
solution and 300 ll 1 M PCA solution. After incubation on ice for
10 min, samples were centrifuged and filtered. Aliquots of 50 ll
were injected in the chromatograph, and sample analysis was per-
formed over a range of 50 ng/ml to 1000 ng/ml.
Assay of erythrocyte S-COMT activity
The same blood samples taken for pharmacokinetic assessments
were used for the preparation of washed erythrocytes for the assay
of S-COMT activity in erythrocytes. After collection, the blood
samples were immediately centrifuged (1500·g, 10 min, 4C) and
the resulting plasma and uppermost cell layer were removed. The
tubes containing the erythrocytes were placed on ice and a volume
of cold 0.9% sodium chloride solution equal to double that of cells
was added. The cells were then mixed, centrifuged and washed
using this procedure three times. Washed cells (250 ll) in 2 ml
Eppendorf tubes were stored at )70C until required for analysis.
S-COMT activity was determined according to the method of
Schultz et al. [19] with minor modifications. In brief, pre-washed
erythrocyte samples were haemolyzed with four volumes of ice-cold
water. After vortexing, the samples were left standing on ice for
10 min and then centrifuged for 20 min at 4C at 20,000·g. The
supernatant was used for S-COMT assay, which was carried out
immediately after sample preparation. The incubation mixture
contained 300 ll enzyme preparation, 375 ll incubation medium
and 75 ll 5 mM adrenaline as the enzyme substrate. The final
reaction volume (750 ll) contained 100 mM sodium phosphate
buffer, pH 7.8, 2 mM MgCl2 and 200 lM S-adenosyl-L-methio-
nine. The samples were incubated in a water bath at 37C for
60 min. The tubes were transferred to ice and the reaction was
stopped by adding 75 ll ice-cold 4 M perchloric acid. After 10 min,
the samples were centrifuged (5000·g, 10 min, 4C) and 500-ll
aliquots of the supernatant, filtered on 0.22-lm pore-size Spin-X
filter tubes (Costar), were used for the assay of metanephrine by
means of high-performance liquid chromatography (HPLC) with
electrochemical detection, as previously described [20, 21].
S-COMT activity was expressed as the amount of metanephrine
formed (as picomoles per milligram of protein per hour).
Analysis
Pharmacokinetic and pharmacodynamic analysis
The pharmacokinetic and pharmacodynamic variables were de-
rived from non-compartmental analysis using WinNonlin Version
4.0 (Pharsight Co, Mountain View, CA, USA). The following
variables for levodopa and 3-OMD were derived, where appro-
priate, from the individual plasma concentration–time: maximum
observed dependent variable value (Cmax), the time of occurrence of
Cmax (tmax), the area under the plasma concentration–time curve
from time zero to the last sampling time at which the levodopa or
3-OMD concentration was at or above the limit of quantification,
calculated by the linear trapezoidal rule (AUC0–t), the area under
the plasma concentration–time curve from time zero to infinity,
calculated from AUC0–t + (Clast/kz), where Clast is the last quan-
tifiable levodopa or 3-OMD concentration (AUC0–¥), the apparent
terminal rate constant calculated by log-linear regression of the
terminal segment of the levodopa and 3-OMD plasma concentra-
tion versus time curve (kz), the apparent terminal half-life (t1/2),
calculated from ln 2/kz. Mean ratios for the pharmacokinetic
variables of levodopa and 3-OMD obtained following adminis-
tration of Madopar 125 concomitantly with each different dose of
BIA 3-202 versus those obtained after administration of Madopar
125 plus placebo were calculated. The following mean pharmaco-
dynamic variables concerning COMT activity (expressed as
metanephrine formed) were derived from the individual COMT
activity profiles: maximum inhibition of COMT activity (Emax),
time to occurrence of Emax (tEmax) and area under the effect–time
curve (AUEC). The pre-dose value was taken as the baseline
value (E0).
The statistical analysis was performed using the Statistica
software package (version 5.5, StatSoft Inc, Tulsa, OK, USA). For
comparisons between BIA 3-202 and placebo, the analysis of var-
iance (ANOVA) was carried out and, when appropriate, the
Newman-Keuls test was used. In all statistical evaluations, signif-
icance was concluded if the 95% confidence interval (95% CI)
excluded the unit.
Tolerability
Individual and summary blood pressure, heart rate, ECG param-
eters, neurological examination and clinical laboratory data were
presented in tabular form with mean, median, standard deviation
and range (min and max) as appropriate. For the laboratory safety
data, out of range values were flagged in the data listings and a list
of clinically significantly abnormal values was presented. Adverse
events were tabulated and summarised according to the Medical
Dictionary for Regulatory Activities (MedDRA, version 4.0).
Results
A total of 18 subjects (12 male and 6 female) were en-
rolled in the study. The mean (±SD) age, height and
weight were 26.8±6.9 years (range 20–45 years),
1.70±0.09 m (range 1.54–1.84 m), 69.1±8.7 kg (range
58.5–89.0 kg), respectively.
Pharmacokinetics
Plasma concentration versus time profiles
and pharmacokinetics of levodopa
Mean plasma levodopa concentration–time profiles and
pharmacokinetic variables obtained following a single
oral administration of Madopar 125 or placebo and BIA
3-202 (50, 100, 200 and 400 mg) are summarised in
Fig. 1 and Table 1. Table 2 depicts the mean ratios of
the pharmacokinetic variables obtained following
administration of Madopar 125 plus BIA 3-202 over
those obtained following administration of Madopar
125 plus placebo.
Mean Cmax values were attained at 1.0 h to 1.3 h
post-dose. Thereafter, plasma levodopa concentrations
declined with a mean elimination half-life increasing in a
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dose-dependent manner, ranging from 1.1 h (placebo) to
1.8 h (400 mg BIA 3-202). Cmax of levodopa did not
differ between different doses of BIA 3-202 and between
BIA 3-202 and placebo. A statistically significant in-
crease in the extent of systemic exposure to levodopa
(AUC0–¥) occurred at all doses of BIA 3-202 tested. The
increase in levodopa AUC ranged from about 40% at
50 mg (BIA 3-202/placebo ratios=1.39) to 80% at
400 mg (BIA 3-202/placebo ratios=1.80). The increase
in levodopa AUC values was slightly higher at 100 mg
BIA 3-202 than that obtained with 200 mg (60% versus
52%).
Plasma concentration versus time profiles
and pharmacokinetic of 3-OMD
Mean plasma 3-OMD concentration–time profiles and
pharmacokinetic variables are presented in Fig. 2 and
Table 3, respectively. BIA 3-202 was found to decrease
in a dose proportional manner the mean Cmax and
AUC0–¥ values, with differences versus placebo being
statistically significant for all the doses tested (Ta-
ble 2).
Pharmacodynamics
Mean COMT inhibition profiles and pharmacodynamic
variables for COMT inhibition are summarised in Fig. 3
and Table 4. Assuming the pre-dose metanephrine
formed as baseline, the maximum COMT inhibition
(Emax) occurred between 1.4 h and 2.0 h post-dose
(tEmax), and ranged from 57% (50 mg) to 84% (400 mg).
At all doses tested, BIA 3-202 significantly (P<0.01)
decreased COMT activity.
Table 2 Mean ratios of the individual pharmacokinetic variables of
levodopa and 3-O-methyl-levodopa (3-OMD) obtained following
administration of Madopar 125 concomitantly with BIA 3-202
versus Madopar 125 plus placebo (n=18 unless otherwise noted).
Cmax peak plasma concentration, AUC area under concentration–
time curve, t1/2 half-life
Levodopa 3-OMD
Cmax AUC0–¥ t1/2 Cmax AUC0–¥ t1/2
50 mg 0.91 1.39 1.23 0.57 0.67 1.12
(0.58, 1.44) (1.06, 1.69)* (0.45–3.18)* (0.45, 0.71) (0.54, 0.84)** (0.45–2.01)**
100 mg 1.06 1.60 1.58 0.41 0.52 1.31
(0.69, 1.63) (1.27, 1.98) (0.54–2.97) (0.35, 0.48) (0.43, 0.63) (0.62–1.82)
200 mg 0.93 1.52 1.56 0.35 0.42 1.40
(0.83, 1.56) (1.22, 1.90) (0.58–3.53) (0.27, 0.45) (0.32, 0.53)* (0.50–2.17)*
400 mg 1.12 1.80 1.65 0.24 0.40 1.78
(0.74, 1.70) (1.43, 2.22) (0.68–3.70) (0.18, 0.32) (0.30, 0.51)** (0.92–2.84)**
Cmax and AUC0-¥ ratios are presented as geometric means and 95% confidence intervals
tmax are presented as median with range values in parentheses
*n=17, **n=16
Table 1 Mean (coefficient of variation, %) pharmacokinetic variables of levodopa following single oral administration of Madopar 125
concomitantly with placebo or BIA 3-202 (n=18 unless otherwise noted). Cmax peak plasma concentration, tmax time to reach Cmax, AUC
area under concentration–time curve, t1/2 half-life
Dose Cmax tmax AUC0–t AUC0–¥ kz t1/2
(ng/ml) (h) (ng h/ml) (ng h/ml) (1/h) (h)
Placebo 1091 (80) 1.0 (0.5–2.0) 1240 (48) 1366 (43) 0.75 (38) 1.1 (43)
50 mg 880 (49) 1.0 (0.5–3.0) 1596 (41) 1809 (38)* 0.58 (31)* 1.3 (27)*
100 mg 1008 (42) 1.0 (0.5–3.0) 2048 (45) 2197 (42) 0.51 (27) 1.4 (22)
200 mg 876 (38) 1.0 (0.5–3.0) 1924 (45) 2083 (42) 0.47 (22) 1.6 (22)
400 mg 1075 (47) 1.3 (0.5–3.0) 2220 (41) 2416 (39) 0.40 (24) 1.8 (23)
tmax values are median with range values in parentheses
*n=17 (terminal monoexponential phase could not be unambiguously identified in one subject)
Fig. 1 Mean plasma levopopa concentration–time profiles follow-
ing single oral administration of Madopar 125 concomitantly with
placebo or BIA 3-202. Symbols indicate means of 18 subjects per
group
606
Tolerability
During the course of the study, 17 (94.4%) of the 18
subjects who participated reported a total of 48 adverse
events. From these adverse events, 32 were assessed as
possibly related to treatments (Madopar 125 and BIA
3-202 or placebo) and 16 adverse events as not related.
There were no serious adverse events, deaths or dis-
continuations due to adverse events. All adverse events
were mild in severity except three adverse events re-
ported by the same subject at different treatment peri-
ods: dizziness (200 mg) and orthostatic hypotension
[100 mg (22% decrease in systolic blood pressure 1 h
after drug administration) and 400 mg (21% decrease in
systolic blood pressure 2 h after drug administration);
on both occasions blood pressure returned to normal
values within 1 h and 2 h, respectively]. The most fre-
quent adverse event was headache (50 mg, four episodes;
100 mg, two episodes; 200 mg, one episode). No pattern
suggesting a relationship between the dose of BIA 3-202
and occurrence of adverse events was detected. There
were no clinically significant abnormalities in clinical
laboratory safety tests, vital signs, and physical exami-
nation or ECG parameters.
Discussion and conclusions
In previous trials in healthy male subjects, BIA 3-202
was shown to be well tolerated and to inhibit COMT in
a potent and reversible manner. The study reported here
was the first aiming to explore the therapeutic potential
of four different doses of BIA 3-202 administered to-
gether with a single dose of standard release levodopa/
benserazide.
The extent of systemic exposure to levodopa, mea-
sured by AUC, increased with increasing doses and the
maximum increase in levodopa AUC values was 80%,
with the dose of 400 mg. Mean tmax and Cmax of levo-
dopa did not change significantly between different do-
ses of BIA 3-202 or between BIA 3-202 and placebo.
Plasma concentrations of levodopa declined with a mean
apparent elimination half-life increasing in a dose-
dependent manner. At 100 mg and 200 mg BIA 3-202,
the t1/2 of levodopa increased approximately 60% versus
placebo (ratios of 1.58 and 1.56, respectively). In a study
by Kaakkola et al. [22], 200 mg entacapone adminis-
tered together with levodopa/benserazide increased the
AUC of levodopa by 38%. This might indicated that
BIA 3-202 is more potent than entacapone at increasing
exposure to levodopa. In the present study, the
increasing exposure to levodopa with 50 mg BIA 3-202
was similar to that obtained 200 mg entacapone, and
higher doses of BIA 3-202 (100, 200 and 400 mg) were
clearly more efficacious. When compared with tolca-
pone, it seems that BIA 3-202 is less potent. In healthy
volunteers that received tolcapone plus 100/25 mg
levodopa/benserazide, the mean AUC of levodopa
approximately doubled with 200 mg tolcapone; in-
creases in the dose of tolcapone to 400 mg and 800 mg
resulted in increases of levodopa AUC values by 90%
and 70%, respectively [23].
BIA 3-202 reduced Cmax and AUC values of 3-OMD
in a dose-dependent manner. Statistically signifi-
cant reductions were found for all doses tested. The
Fig. 3 Mean S-COMT activity (pmol/mg protein/h) profile from
baseline (pre-dose) following single oral administration of Mado-
par 125 concomitantly with placebo or BIA 3-202. Symbols indicate
means of 18 subjects per group
Fig. 2 Mean plasma 3-O-mehtyl-levodopa concentration–time
profiles following single oral administration of Madopar 125
concomitantly with placebo or BIA 3-202. Symbols indicate means
of 18 subjects per group
Table 3 Mean (coefficient of variation, %) pharmacokinetic vari-
ables of 3-O-methyl-levodopa following single oral administration
of Madopar 125 concomitantly with placebo and BIA 3-202 (n=18
unless otherwise noted). Cmax peak plasma concentration, tmax time
to reach Cmax, AUC area under concentration–time curve, t1/2 half-
life
Cmax tmax AUC0–¥ t1/2
(ng/ml) (h) (ng h/ml) (h)
Placebo 579 (26) 4.0 (1.0–6.0) 11717 (26) 11.7 (26)
50 mg 333 (35) 5.0 (0.5–8.0) 7278 (58)** 12.1 (46)**
100 mg 239 (27) 4.0 (1.0–8.0) 6189 (34) 14.4 (18)
200 mg 228 (62) 5.0 (0.5–12.0) 4989 (61)* 13.8 (37)*
400 mg 163 (69) 4.0 (1.0–12.0) 4479 (74)** 16.9 (45)**
tmax values are median with range values in parentheses
*n=17; **n=16 (terminal monoexponential phase could not be
unambiguously identified in one and two subjects, respectively)
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formation of 3-OMD from levodopa is dependent on the
COMT activity, particularly at the intestinal level, the
main site of O-methylation of levodopa. The marked
dose-dependent reduction in the 3-OMD levels indicates
that BIA 3-202 may not only inhibit S-COMT in ery-
throcytes, but also in other organs, namely those rich in
COMT such as the liver, kidney and intestine. In fact,
BIA 3-202 was found to be equipotent at inhibiting liver
S-COMT and erythrocyte S-COMT in the rat [17]. In
the present study, 100 mg and 200 mg BIA 3-202
achieved a reduction in the AUC of 3-OMD of about
50% and 65%, respectively.
The observed erythrocyte S-COMT activity indicates
that BIA 3-202 at all doses tested induced a significant
decrease in COMT activity. COMT inhibition ranged
from 57% (50 mg) to 84% (400 mg). At 200 mg BIA
3-202, inhibition of S-COMT in erythrocytes reached the
80% reduction level, a value that is superior to that
obtained with 200 mg entacapone (approximately 65%)
[24] and slightly below that reported for tolcapone
(87%) [23].
Though elderly subjects, such as patients afflicted
with Parkinsons disease, may handle levodopa differ-
ently, namely concerning its intestinal absorption [25], it
is not anticipated that the efficacy of BIA 3-202 in pre-
venting levodopa O-methylation may be compromised
in parkinsonian patients. The O-methylation of levo-
dopa has been demonstrated as a major event in the
disposition of levodopa in young and elderly subjects
and other COMT inhibitors, such as tolcapone and
entacapone, effectively increase levodopa availability in
an age-independent manner [26, 27, 28].
BIA 3-202 showed a favourable tolerability profile.
The adverse events reported here were usually mild and
transient. Most of the reported adverse events are
characteristic of levodopa. The appearance of headache,
dizziness and orthostatic hypotension in BIA 3-202
groups may be related to the increase in the AUC of
levodopa and not necessarily be a consequence of a di-
rect effect of BIA 3-202 administration. No correlation
between adverse events and the dose of BIA 3-202 was
apparent.
In conclusion, the novel COMT inhibitor BIA 3-202
was found to significantly increase the bioavailability of
levodopa and to reduce the formation of 3-OMD when
administered concomitantly with standard release levo-
dopa/benserazide. Therefore, BIA 3-202 may have
therapeutic utility as an adjunct to levodopa therapy in
patients afflicted with Parkinsons disease. Clinical trials
in patients with Parkinsons disease are, therefore, re-
quired to evaluate clinical improvements of BIA 3-202.
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